Clinical Trial Search

Primary: Difference in Inverse Serum Creatinine Within Patients' Slopes Between the Placebo AGAL-008-00 (NCT00074984) and Fabrazyme AGAL02503 (NCT00081497) Periods — -0.044…

Primary: Number of Participants Experiencing a Clinically Significant Renal, Cardiac or Cerebrovascular Event and/or Death in Fabrazyme (Agalsidase Beta) Patients as Compared to…

Primary: Blood Oxygenation at the Optic Nerve Head — 60.8; 65.3 percentage of oxygen saturation

Primary: Estimated Glomerular Filtration Rate (eGFR) — -0.66; -0.32 ml/min/month — p=0.01

Primary: Globotriaosylceramide (GL-3) Clearance in Capillary Endothelium in the Skin — 2; 14; 5; 0 patients

Primary: Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium — 3; 21; 18; 17 Participants

Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 9 Participants

Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) - All — 2; 2; 3; 2 Participants

Primary: Total Time Spent by Healthcare Professionals (HCPs) in the Preparation/Administration of a Single Dose of ERT in Patients With Fabry Disease — 151.9 minutes

Primary: Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI) — 3.2; 0.5; -10.3 g/m^2.7

Primary: Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 — -3.31; -6.34 percent change

Primary: Neuropathic Pain Monthly Score: Change From Baseline to Month 6 — -1.64; -2.05 score on a scale — p=0.3189

Primary: Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate — -4.35; -3.24 mL/min/1.73 m^2/year

Primary: Adverse Events — 54; 11; 29; 14 adverse events